Literature DB >> 15449637

The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey.

Karin S Coyne1, Chris Payne, Samir K Bhattacharyya, Dennis A Revicki, Christine Thompson, Ron Corey, Timothy L Hunt.   

Abstract

OBJECTIVES: Overactive bladder (OAB) is described as urinary urgency, with and without urge incontinence and usually with frequency and nocturia. Most attention to OAB's impact on health-related quality of life (HRQL), however, has focused on urge incontinence. The objective of this study was to evaluate the burden of OAB, specifically urinary urgency and frequency on HRQL.
METHODS: In the National Overactive Bladder Evaluation Program (NOBLE), a computer-assisted telephone interview survey was conducted to assess the prevalence of OAB in the United States. Based on interview responses, respondents were classified into three groups: continent OAB, incontinent OAB, and controls. To evaluate the HRQL impact of OAB, HRQL questionnaires were mailed to all respondents with OAB and age- and sex-matched controls as a performed nested case-control study. Continuous data were compared using Student's t tests and analysis of variance with post hoc pairwise comparisons; results were adjusted for age, sex, and comorbid conditions. Multivariable regressions were performed to assess the impact of each urinary variable on symptom bother and HRQL.
RESULTS: A total of 919 participants responded to the questionnaires (52% response rate) with a mean age of 54.2 years (SD 16.4 years); 70.4% were female and 85% were white. Continent OAB participants comprised 24.8% of the sample, incontinent OAB 18.3%, and controls 56.9%. In each regression analysis, urinary urge intensity accounted for the greatest variance for increases in symptom bother and decreases in HRQL.
CONCLUSIONS: The experience of urinary urgency has a significant negative effect on HRQL and increases symptom bother, an effect that, in this community sample, is greater than that of incontinence, frequency, or nocturia.

Entities:  

Mesh:

Year:  2004        PMID: 15449637     DOI: 10.1111/j.1524-4733.2004.74008.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  72 in total

1.  Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?

Authors:  Eleni Pitsouni; Themos Grigoriadis; Matthew Falagas; Angeliki Tsiveleka; Stefano Salvatore; Stavros Athanasiou
Journal:  Lasers Med Sci       Date:  2017-08-02       Impact factor: 3.161

Review 2.  Translational Research and Functional Changes in Voiding Function in Older Adults.

Authors:  Florenta Aura Kullmann; Lori Ann Birder; Karl-Erik Andersson
Journal:  Clin Geriatr Med       Date:  2015-07-23       Impact factor: 3.076

3.  Factors associated with urinary incontinence in a community sample of young nulligravid women.

Authors:  Casey G Kowalik; Adam Daily; Sophia D Goodridge; Siobhan M Hartigan; Melissa R Kaufman; Jay H Fowke; Roger R Dmochowski; William S Reynolds
Journal:  Neurourol Urodyn       Date:  2020-04-23       Impact factor: 2.696

4.  Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies.

Authors:  Peter K Sand; John Heesakkers; Stephen R Kraus; Martin Carlsson; Zhonghong Guan; Sandra Berriman
Journal:  Drugs Aging       Date:  2012-02-01       Impact factor: 3.923

Review 5.  What's a 'cure'? Patient-centred outcomes of treatments for stress urinary incontinence.

Authors:  R M Freeman
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-09-12

6.  Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.

Authors:  Linda Cardozo; David Castro-Diaz; Marc Gittelman; Arwin Ridder; Moses Huang
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-04-20

Review 7.  Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Authors:  Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

Review 8.  The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Authors:  Karl-Erik Andersson; Nurul Choudhury; Jean-Nicolas Cornu; Moses Huang; Cees Korstanje; Emad Siddiqui; Philip Van Kerrebroeck
Journal:  Ther Adv Urol       Date:  2018-07-06

Review 9.  Flavoxate in urogynecology: an old drug revisited.

Authors:  Murat Zor; Emin Aydur; Roger Roman Dmochowski
Journal:  Int Urogynecol J       Date:  2014-12-06       Impact factor: 2.894

Review 10.  Perspectives on overactive bladder in the elderly population.

Authors:  Masaki Yoshida
Journal:  World J Urol       Date:  2009-11-11       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.